Neuphoria Therapeutics In... (NEUP)
Neuphoria Therapeutics Statistics
Share Statistics
Neuphoria Therapeutics has 1.76M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 1.76M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 4.04K |
| FTD / Avg. Volume | 2.92% |
Short Selling Information
The latest short interest is 35.38K, so 2.01% of the outstanding shares have been sold short.
| Short Interest | 35.38K |
| Short % of Shares Out | 2.01% |
| Short % of Float | 2.02% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -80.06 and the forward PE ratio is null. Neuphoria Therapeutics's PEG ratio is 1.2.
| PE Ratio | -80.06 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 70.92 |
| P/FCF Ratio | -84.49 |
| PEG Ratio | 1.2 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Neuphoria Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.45, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.45 |
| Quick Ratio | 3.45 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.94M |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -87.32K |
| Effective Tax Rate | 0.56% |
Stock Price Statistics
The stock price has increased by -55.34% in the last 52 weeks. The beta is 0.26, so Neuphoria Therapeutics's price volatility has been higher than the market average.
| Beta | 0.26 |
| 52-Week Price Change | -55.34% |
| 50-Day Moving Average | 5.16 |
| 200-Day Moving Average | 5.3 |
| Relative Strength Index (RSI) | 51.3 |
| Average Volume (20 Days) | 138.56K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -17.89M |
| Net Income | -15.49M |
| EBITDA | -17.13M |
| EBIT | -17.8M |
| Earnings Per Share (EPS) | -0.12 |
Balance Sheet
The company has 12.61M in cash and 272.74K in debt, giving a net cash position of 12.34M.
| Cash & Cash Equivalents | 12.61M |
| Total Debt | 272.74K |
| Net Cash | 12.34M |
| Retained Earnings | -177.98M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -14.68M and capital expenditures 0, giving a free cash flow of -14.68M.
| Operating Cash Flow | -14.68M |
| Capital Expenditures | 0 |
| Free Cash Flow | -14.68M |
| FCF Per Share | -0.1 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NEUP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for NEUP is $21, which is 305.4% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21 |
| Price Target Difference | 305.4% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Dec 24, 2024. It was a backward split with a ratio of 1:12.
| Last Split Date | Dec 24, 2024 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |